Icotinib (BioDeep_00000858834)
代谢物信息卡片
Icotinib
化学式: C22H21N3O4 (391.1532)
中文名称: 埃克替尼
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C#CC1=CC(=CC=C1)NC2=NC=NC3=CC4=C(C=C32)OCCOCCOCCO4
InChI: InChI=1S/C22H21N3O4/c1-2-16-4-3-5-17(12-16)25-22-18-13-20-21(14-19(18)23-15-24-22)29-11-9-27-7-6-26-8-10-28-20/h1,3-5,12-15H,6-11H2,(H,23,24,25)
描述信息
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EB - Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163952 - EGFR-targeting Agent
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
同义名列表
1 个代谢物同义名
数据库引用编号
5 个数据库交叉引用编号
- KEGGdrug: D11251
- PubChem: 22024915
- DrugBank: DB11737
- ChEMBL: CHEMBL2087361
- CAS: 610798-31-7
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Xin Xiong, Yuanyuan Zhang, Ziyu Wang, Congya Zhou, Ping Yang, Xin Du, Li Yang, Wei Liu. Simultaneous quantitative detection of afatinib, erlotinib, gefitinib, icotinib, osimertinib and their metabolites in plasma samples of patients with non-small cell lung cancer using liquid chromatography-tandem mass spectrometry.
Clinica chimica acta; international journal of clinical chemistry.
2022 Feb; 527(?):1-10. doi:
10.1016/j.cca.2021.12.028. [PMID: 34999058] - Xin Li, Minghui Liu, Hongbing Zhang, Hongyu Liu, Jun Chen. Clinical study of apatinib combined with EGFR-TKI in the treatment of chronic progression after EGFR-TKI treatment in non-small cell lung cancer (ChiCTR1800019185).
Thoracic cancer.
2020 03; 11(3):819-826. doi:
10.1111/1759-7714.13303. [PMID: 31918452] - Yiming Yu, Maidinaimu Abudula, Chaofen Li, Zhongbo Chen, Yun Zhang, Yichen Chen. Icotinib-resistant HCC827 cells produce exosomes with mRNA MET oncogenes and mediate the migration and invasion of NSCLC.
Respiratory research.
2019 Oct; 20(1):217. doi:
10.1186/s12931-019-1202-z. [PMID: 31606039] - Junhui Wang, Jianxin Chen. Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: a case report.
BMC cancer.
2019 Feb; 19(1):131. doi:
10.1186/s12885-019-5352-7. [PMID: 30736738] - Lunfei Liu, Honggang Lou, Jiong Zhou, Ying Shen, Min Zheng, Zourong Ruan. Pharmacokinetics and Safety of Icotinib Hydrochloride Cream in Patients with Mild to Moderate Chronic Plaque Psoriasis: A Randomized Double-Blind Vehicle-Controlled Phase 1 Study.
BioMed research international.
2019; 2019(?):9072683. doi:
10.1155/2019/9072683. [PMID: 31187048] - Ying Xiao, Piera Maiolino, Jin-Hua Yan, Jie Ma, Jin Li, Li Chen. Validation of an LC-MS/MS method for simultaneous determination of icotinib and its four major circulating metabolites in human plasma and its application in a pharmacokinetic study.
Biomedical chromatography : BMC.
2018 Nov; 32(11):e4327. doi:
10.1002/bmc.4327. [PMID: 29975793] - Yubo Wang, Li Li, Rui Han, Lin Jiao, Jie Zheng, Yong He. Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib.
Lung cancer (Amsterdam, Netherlands).
2018 04; 118(?):105-110. doi:
10.1016/j.lungcan.2018.02.007. [PMID: 29571987] - Ai-Ying Jiang, Jing Zhang, Hai-Long Luo, Feng Gao, Yu-Feng Lv. Icotinib and whole-brain radiotherapy for the treatment in patients with brain metastases from EGFR-mutant nonsmall cell lung cancer: A retrospective study.
Medicine.
2018 Apr; 97(15):e0312. doi:
10.1097/md.0000000000010312. [PMID: 29642161] - Shun Lu, Ming Ye, Lieming Ding, Fenlai Tan, Jie Fu, Bin Wu. Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.
Oncotarget.
2017 Feb; 8(6):9996-10006. doi:
10.18632/oncotarget.14310. [PMID: 28036283] - Wenxian Wang, Zhengbo Song, Yiping Zhang. A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance.
Cancer medicine.
2017 01; 6(1):154-162. doi:
10.1002/cam4.978. [PMID: 28000387] - Lin Zhou, Jiazhuo He, Weijie Xiong, Yongmei Liu, Jing Xiang, Qin Yu, Maozhi Liang, Xiaojuan Zhou, Zhenyu Ding, Meijuan Huang, Li Ren, Jiang Zhu, Lu Li, Mei Hou, Lieming Ding, Fenlai Tan, You Lu. Impact of whole brain radiation therapy on CSF penetration ability of Icotinib in EGFR-mutated non-small cell lung cancer patients with brain metastases: Results of phase I dose-escalation study.
Lung cancer (Amsterdam, Netherlands).
2016 06; 96(?):93-100. doi:
10.1016/j.lungcan.2016.04.003. [PMID: 27133757] - Hua-xin Zhang, Hang-xing Xiong, Li-wei Li. Investigation on the protein-binding properties of icotinib by spectroscopic and molecular modeling method.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.
2016 May; 161(?):88-94. doi:
10.1016/j.saa.2016.02.014. [PMID: 26963729] - Yun Fan, Zhiyu Huang, Luo Fang, Lulu Miao, Lei Gong, Haifeng Yu, Haiyan Yang, Tao Lei, Weimin Mao. A phase II study of icotinib and whole-brain radiotherapy in Chinese patients with brain metastases from non-small cell lung cancer.
Cancer chemotherapy and pharmacology.
2015 Sep; 76(3):517-23. doi:
10.1007/s00280-015-2760-5. [PMID: 26148750] - Jun Ni, Dong-Yang Liu, Bei Hu, Chen Li, Ji Jiang, Han-Ping Wang, Li Zhang. Relationship between icotinib hydrochloride exposure and clinical outcome in Chinese patients with advanced non-small cell lung cancer.
Cancer.
2015 Sep; 121 Suppl 17(?):3146-56. doi:
10.1002/cncr.29568. [PMID: 26331821] - Dongyang Liu, Li Zhang, Yiwen Wu, Ji Jiang, Fenlai Tan, Yingxiang Wang, Yong Liu, Pei Hu. Clinical pharmacokinetics, safety, and preliminary efficacy evaluation of icotinib in patients with advanced non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands).
2015 Sep; 89(3):262-7. doi:
10.1016/j.lungcan.2015.05.024. [PMID: 26162563] - Pei Hu, Jia Chen, Dongyang Liu, Xin Zheng, Qian Zhao, Ji Jiang. Development of population pharmacokinetics model of icotinib with non-linear absorption characters in healthy Chinese volunteers to assess the CYP2C19 polymorphism and food-intake effect.
European journal of clinical pharmacology.
2015 Jul; 71(7):843-50. doi:
10.1007/s00228-015-1864-5. [PMID: 25995169] - Gaoguang Song, Yujie Liu, Yanying Wang, Guanjun Ren, Shuai Guo, Junling Ren, Li Zhang, Zhili Li. Personalized biomarkers to monitor disease progression in advanced non-small-cell lung cancer patients treated with icotinib.
Clinica chimica acta; international journal of clinical chemistry.
2015 Feb; 440(?):44-8. doi:
10.1016/j.cca.2014.11.010. [PMID: 25447696] - Dongyang Liu, Ji Jiang, Li Zhang, Fenlai Tan, Yingxiang Wang, Don Zhang, Pei Hu. Clinical pharmacokinetics of Icotinib, an anti-cancer drug: evaluation of dose proportionality, food effect, and tolerability in healthy subjects.
Cancer chemotherapy and pharmacology.
2014 Apr; 73(4):721-7. doi:
10.1007/s00280-014-2398-8. [PMID: 24488324] - Jia Chen, Xin Zheng, Dong-Yang Liu, Qian Zhao, Yi-Wen Wu, Fen-Lai Tan, Yin-Xiang Wang, Ji Jiang, Pei Hu. Therapeutic effects and adverse drug reactions are affected by icotinib exposure and CYP2C19 and EGFR genotypes in Chinese non-small cell lung cancer patients.
Asian Pacific journal of cancer prevention : APJCP.
2014; 15(17):7195-200. doi:
10.7314/apjcp.2014.15.17.7195. [PMID: 25227813] - Jue-Fang Ding, Da-Fang Zhong. [Clinical pharmacokinetics of small molecule tyrosine kinase inhibitors].
Yao xue xue bao = Acta pharmaceutica Sinica.
2013 Jul; 48(7):1080-90. doi:
NULL. [PMID: 24133973] - Can-Jun Ruan, Dong-Yang Liu, Ji Jiang, Pei Hu. Effect of the CYP2C19 genotype on the pharmacokinetics of icotinib in healthy male volunteers.
European journal of clinical pharmacology.
2012 Dec; 68(12):1677-80. doi:
10.1007/s00228-012-1288-4. [PMID: 22585284] - Dongyang Liu, Ji Jiang, Li Zhang, Fenlai Tan, Yingxiang Wang, Pei Hu. Metabolite characterization of a novel anti-cancer agent, icotinib, in humans through liquid chromatography/quadrupole time-of-flight tandem mass spectrometry.
Rapid communications in mass spectrometry : RCM.
2011 Aug; 25(15):2131-40. doi:
10.1002/rcm.5061. [PMID: 21732454] - Dongyang Liu, Ji Jiang, Pei Hu, Fenlai Tan, Yingxiang Wang. Quantitative determination of icotinib in human plasma and urine using liquid chromatography coupled to tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2009 Nov; 877(30):3781-6. doi:
10.1016/j.jchromb.2009.08.055. [PMID: 19833564] - Zhongmin Guan, Xiaoyan Chen, Yinxiang Wang, Dafang Zhong. Metabolite identification of a new antitumor agent icotinib in rats using liquid chromatography/tandem mass spectrometry.
Rapid communications in mass spectrometry : RCM.
2008 Jul; 22(14):2176-84. doi:
10.1002/rcm.3599. [PMID: 18536068]
